Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407003 | 0.91 | ALKBH1 (0.36) | HCAR3MAOAMAOBNR3C1KDM4C | |
| SCHEMBL1406887 | 0.91 | NR3C1 (0.42) | HCAR3MAOAMAOBNR3C1KDM4C | |
| SCHEMBL3290176 | 0.84 | ALKBH1 (0.35) | MAOAMAOBNR3C1KDM4CALKBH1 | |
| SCHEMBL1406998 | 0.82 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL27758253 | 0.81 | ALDH1A1 (0.43) | HCAR3MAOAMAOBKDM4CALDH1A1 | |
| SCHEMBL4716749 | 0.79 | AGTR1 (0.41) | HCAR3ALKBH1NR4A3 | |
| SCHEMBL3289959 | 0.78 | KDM4C (0.37) | HCAR3MAOAMAOBNR3C1KDM4C | |
| SCHEMBL4968650 | 0.78 | POLB (0.42) | ALKBH1ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL1406899 | 0.78 | POLB (0.47) | HCAR3KDM4CPTGER4LRRK2ALDH1A1 | |
| SCHEMBL19321046 | 0.77 | HCAR3 (0.38) | HCAR3MAOAMAOBNR3C1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1999114-B1 | PYRAZOLES AS 11-BETA-HSD-1 | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| CN-101405270-B | Pyrazoles as 11-beta-HSD-1 | HOFFMANN LA ROCHE | 2013-01-16 | — | — | CN | disclosed |
| EP-2295411-A1 | Pyrazoles as 11-beta-hsd-1 | F. Hoffmann-La Roche AG (CH) | 2011-03-16 | — | — | EP | disclosed |
| US-7728029-B2 | Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | disclosed |
| CN-101405270-A | Pyrazoles as 11-beta-HSD-1 | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | CN | disclosed |
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | ANDERSON KEVIN WILLIAM | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD3B2, HSD3B1, HSD17B2 | HCAR3 1025/4885MAOA 1381/4885MAOB 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.